Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orelabrutinib + obinutuzumab
- Development stage
- Unknown
- Lead developer
- InnoCare Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Orelabrutinib + obinutuzumab is a combination therapy under investigation for the treatment of B-cell malignancies, particularly marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL). Orelabrutinib is a highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor that disrupts B-cell receptor signaling, leading to inhibition of malignant B-cell proliferation and survival. Obinutuzumab is a type II anti-CD20 monoclonal antibody that induces direct cell death and enhances antibody-dependent cellular cytotoxicity against CD20-expressing B cells. The combination aims to provide a chemotherapy-free regimen with high efficacy and manageable safety in previously untreated MZL patients. Preliminary clinical data show promising objective response rates and complete remission rates in first-line settings for MZL[2][7][9].
- Brand names
- Yinuokai + GazyvaYinuokai + Gazyvaro
- Other names
- O2 regimenO-2 regimenO 2 regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on orelabrutinib + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orelabrutinib + obinutuzumab.